CVRx, Inc., a private medical device company, announced today that its BeAT-HF phase III randomized clinical trial results were published in the Journal of the American College of Cardiology (“JACC”)
| MINNEAPOLIS, June 30, 2020 /PRNewswire/ -- CVRx, Inc., a private medical device company, announced today that its BeAT-HF phase III randomized clinical trial results were published in the Journal of the American College of Cardiology (“JACC”). Results from the trial were used to obtain Premarket Approval (PMA) from the United States Food and Drug Administration (“FDA”) to market its BAROSTIM NEO device for improvement of symptoms in patients with heart failure (“HF”) in the United States.
“Publication of the BeAT-HF trial results in the esteemed, peer reviewed JACC journal provides further validation that we finally have an effective neuromodulation therapy for advanced HF patients, who did not have access to device-based therapy.” said Michael Zile, M.D., Professor of Medicine at the Medical University of South Carolina and Chair Person of the BeAT-HF Executive Steering Committee. “The BAROSTIM NEO improves patient-centered symptomatic endpoints of quality of life score, exercise capacity and functional status. These results are supported by objective evidence of a significant reduction in NT-proBNP, which in recent studies was associated with a lower rate of cardiovascular death or heart failure hospitalization.” “The interactive and adaptive design of BeAT-HF is groundbreaking,” wrote James L. Januzzi, M.D. and Nasrien E. Ibrahim, M.D. (Massachusetts General Hospital, Harvard Medical School) in their editorial. “With growing incidence, prevalence, and risk of patients affected by HF, all hands must be on deck to ‘beat the clock’ and get safe, effective treatments to our patients.” BeAT-HF was a multi-center, prospective, randomized, controlled trial. Patients were randomized one-to-one to receive BAROSTIM NEO plus optimal medical management or optimal medical management alone (control). Key Qualifications:
The BeAT-HF trial results represent the intended use population that reflects the FDA approved instructions for use included 264 randomized patients. Key six-month results:
* Major adverse neurological and cardiovascular related device or procedure event free rate (MANCE) About BAROSTIM NEO About CVRx, Inc. CVRx Contact: References: CVRx, BAROSTIM NEO and BAROSTIM THERAPY are trademarks of CVRx, Inc. registered in the United States Trademark Office.
SOURCE CVRx, Inc. |
View original content to download multimedia:
